Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
diphtheria toxoid + pertussis vaccine + tetanus toxoid + inactivated poliovirus vaccine
- Development stage
- Phase 4
- Lead developer
- Daiichi Sankyo
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
Squarekids is a quadrivalent combination vaccine (DPT-IPV) indicated for the active immunization of infants against diphtheria, tetanus, pertussis, and poliomyelitis. Developed through a collaboration between GSK and Daiichi Sankyo, it is specifically manufactured and marketed in Japan. The vaccine formulation includes diphtheria toxoid, tetanus toxoid, acellular pertussis antigens (including pertussis toxoid and filamentous hemagglutinin), and inactivated poliovirus derived from Sabin strains (sIPV). By combining these four components into a single subcutaneous injection, Squarekids simplifies the pediatric vaccination schedule in Japan. It is often evaluated for co-administration with other infant vaccines, such as the rotavirus vaccine Rotarix, to ensure immunogenicity and safety are maintained during routine immunization.
- Brand names
- Squarekids
- Other names
- Adsorbed Diphtheria-Purified Pertussis-Tetanus-Inactivated Polio (Sabin strain) Combined VaccineDPT-IPV Squarekids
02
Targets
BCR (Immunoglobulin G B Cell Receptor)
Beyond the preview
Go deeper on diphtheria toxoid + pertussis vaccine + tetanus toxoid + inactivated poliovirus vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on diphtheria toxoid + pertussis vaccine + tetanus toxoid + inactivated poliovirus vaccine.